Stephen Willey

In a report published Monday, Stifel analyst Stephen Willey initiated coverage on Conatus Pharmaceuticals (NASDAQ: CNAT) with a Buy rating and $16.00 price target. In the report, Stifel noted, “We are initiating coverage on shares of Conatus Pharmaceuticals, Inc. (CNAT) with a Buy rating and a 12-...

In a report published Thursday, Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on InterMune (NASDAQ: ITMN), and raised the price target from $17.00 to $18.00. In the report, Stifel Nicolaus noted, “We believe 4Q13 now likely represents the long-awaited inflection point investors...

Analyst Stephen Willey of Thomas Weisel maintains his "market weight" rating on Onyx Pharmaceuticals (NASDAQ: ONXX). The 12-month target price for ONXX is set to $29. According to Thomas Weisel, an exploratory open-label trial (BATTLE) “could generate a positive tailwind for ONXX shares in the near...

Analyst Stephen Willey of Thomas Weisel maintains his "overweight" rating on Anadys Pharmaceuticals Inc (NASDAQ: ANDS). The 12-month target price for ANDS is set to $7. According to Thomas Weisel, “There had been some investor concern around the high placebo response rate observed in the placebo...

Thomas Weisel Partners analyst Stephen Willey maintained his Overweight rating for shares of InterMune, Inc. (Nasdaq: ITMN) and raised the price target from $26 to $55. The day before, a panel at the Food and Drug Administration recommended InterMune's pirfenidone for the treatment of idiopathic...